The question is when. The Baker Brothers own 24%+ of the stock. They can't sell all that stock. If they did the stock would crater and that would hurt them. They are in it to win it. They know the inside scoop and will do like they did with PCYC. They will eventually present some positive news and cruse the 'shorts' which will give us a nice gain then the news of a buyer or buyers will surface then the stock will skyrocket. I will be going along on that ride with them. You will see.......I just don't know when.
Sentiment: Strong Buy
This to me is just healthy consolidation, but the MM of SGEN are very skillful at keeping the SP low and still deliver on the large buy requests; until of course it moves violently higher on large volume. The FDA ruling is only 4-5 weeks away, a positive outcome is almost a sure thing. We should be higher by then.
Losing a bit of ground in recent days, fairly sizeable loss today on low volume. Shorts taking advantage to cover?
Large block registered just after market close; must have accumulated throughout the day from retail sellers. Interesting that someone (BB?) buying. Again?
seems like that might put us in play... I think SGEN is #1 (Boardwalk) in this space and JUNO is #2 (Parkplace)... they were #1 but their most recent results were not strong enough... plot thickens... I would think this deal makes it so CELG buys Juno at some point down the road. Parkplace is gone... what will someone pony up for Boardwalk...
drop to $45 so I can buy like a fiend... or blast past $50 so my options kick in... We need to fall back or go up by more than $3 a week, week in week out... I am just plain SGEN greedy!!!
If you click on your name this is your post on like 40 stocks... kind of goofy.
The only issue is if it becomes part of a major do they mess it up because they are valued more on current earnings than SGEN. But then you have to be thinking if you are a major player in the cancer space right now you know you won't be 5-7 years from now because the technology is changing so rapidly and SGEN is the future leader. But out of our hands it is whatever the BB have in store for the company.
I agree...totally. Great commentary.
The BBs will make a fortune on the combined SGEN-UNUM relationship...I'm just glad to be tagging along for the ride.
Looking at UNUM and its Antibody-Coupled T-cell Receptor (ACTR) technology, are discovering and developing new cellular immunotherapies for cancer. Their vision is of a single cell therapy that can be applied to the treatment of many different cancers. They recently went into a Series B Financing for $65M. This leads me to believe that what SGEN is seeing is the expanded opportunities based upon Dario Campana's work where he created the CD19 chimeric antigen receptor (CAR) that was subsequently shown to be highly effective in treating patients with ALL, an aggressive form of leukemia. He has extensive experience managing clinical cell therapy trials in oncology. Was this an inexpensive way of controlling the future of ALL treatment? SGEN will make an upfront payment of $25 million and an equity investment of $5 million in Unum’s next round of private financing.
I believe that the real benefit here is the expansion into other areas of cancer. The ACTR technology is a chimeric protein that combines components from receptors normally found on two different human immune cell types – natural killer (NK) cells and T-cells – to create a novel cancer cell killing activity. T-cells bearing the ACTR receptor can be directed to attack tumor cells by providing a monoclonal antibody that binds to antigens on the cancer cell surface and then acts as a bridge to the ACTR T-cell, enabling tumor cell killing. Unum has built a platform for cancer treatment based upon ACTR. In contrast to other approaches that are limited to a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigen and may have applications for treating many types of cancers.
The combination of the SGEN and the UNUM approach should accelerate the rapid expansion of targets. I am willing to bet that the BBs were instrumental in finding and bringing about the deal. This could be the cheapest $30 investment in biotech.
Thanks for sharing your DD results.
This board is the best all around YMB because it is populated with people knowledgeable and with propensity to share their research findings and discuss facts courteously and within the bounds of civility. Don't like to use the word, but in this case it really fits in the most well meaning way; you guys and gals have real class.
From GEVA's 5/22/15 SC 14D9:
Dr. Bell confirmed to Dr. Baker that it was a requirement for Alexion that Dr. Baker agree to be appointed to the Alexion Board following consummation of the transaction between the parties.
Baker Bros held in the highest regards and are a premium for any potential suitor of SGEN.
Same for INCY.
Sentiment: Strong Buy
Excuse the word "puts" as I was attempting to abbreviate patients without realizing spellcheck was changing pts to puts.
I should have mentioned from the start that this was in DLBCL patients.
There were quite a few oral presentations re brentuximab vedotin at this conference. Many from investigator sponsored trials, all of which further confirmed the efficacy of BV and it's use with other treatment options.
You can look up the conference and go to the abstract book and look under the section titled "oral presentations" and find the abstracts.
Updated Adcetris + R CHOP in high intermediate/ high risk patients is very interesting. At ASH in Dec. the initial results were published after 12 puts had been treated. At that time the ORR was 92% with CR of 58%. The ASH paper said a recent study of Rchop alone in that patient group showed a CR rate of 26%. At that point in time the CR rate had more than doubled.
With this most recent update 51 patients have been treated, 62 % high int, 38% high risk. Slightly more high risk than from December. The 1.8 mg Adcetris group was scaled back to 1.2 mg to lessen neuropathy AEs. Of 51 puts treated 30 had EOT assessment.
At EOT of treatment ORR was 97% with CR rate of 80%. In the CD 30+ pts CR rate was 86%. 75% CR rate in CD 30- group. In follow up, none of the CD 30+ puts had progressed, with a median PFS of 5 months. 4 of the 16 CD 30- puts did progress.
Pretty amazing results in this at risk DLBCL group.